Drugmakers, insurers, hospitals, pharmacies, medical devices, clinical updates, and healthcare business leaders.
A sharp split in recent earnings performance has intensified the “value versus growth” discussion in U.S. healthcare, with Bristol Myers Squibb posting a net income rebound and Eli Lilly reporting more than double the profit level.
THE APEX TIMES
THE APEX TIMES
The agreement gives Pfizer access to Enodia Therapeutics’ proprietary Sec61 inhibitor know-how as the drugmaker looks for new ways to target protein translocation, a pathway used by cells to process key proteins.
THE APEX TIMES
The Aetna brand of CVS Health is funding a nonprofit education program in 40 schools across six states, highlighting how insurers are tying community health goals to childhood nutrition and movement.
THE APEX TIMES
The insurer and health services company said it raised its full-year earnings expectations following stronger-than-anticipated third-quarter results.
THE APEX TIMES
The insurer’s stock gained about 3.9% in pre-market trading after it reported third-quarter 2026 financial results that beat expectations and increased its full-year profit outlook.
THE APEX TIMES
After a reported 96% run, attention is shifting to whether HCA Healthcare’s earnings and free-cash flow outlook can justify the current share price, or whether the stock could trade at a discount if growth assumptions change.
THE APEX TIMES
The company reported stronger-than-expected results, yet shares dropped the same day, a reminder that investors often react more to outlook and risk outlines than to a single quarter’s profit.
THE APEX TIMES
The collaboration, described by Prelude, is expected to start patient enrollment in the fourth quarter of 2026, beginning with monotherapy dose escalation before moving to combination cohorts.
THE APEX TIMES
The healthcare giant raised its guidance for the year, yet its update did not fully satisfy Wall Street expectations, sending its stock lower on the news.
